NO20091553L - Fenylderivater og deres anvendelse som immunmodulatorer - Google Patents

Fenylderivater og deres anvendelse som immunmodulatorer

Info

Publication number
NO20091553L
NO20091553L NO20091553A NO20091553A NO20091553L NO 20091553 L NO20091553 L NO 20091553L NO 20091553 A NO20091553 A NO 20091553A NO 20091553 A NO20091553 A NO 20091553A NO 20091553 L NO20091553 L NO 20091553L
Authority
NO
Norway
Prior art keywords
immunomodulators
phenyl derivatives
derivatives
formula
preparation
Prior art date
Application number
NO20091553A
Other languages
English (en)
Inventor
Martin Bolli
Oliver Nayler
Claus Mueller
Boris Mathys
David Lehmann
Beat Steiner
Jorg Velker
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of NO20091553L publication Critical patent/NO20091553L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/061,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/101,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/1071,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with two aryl or substituted aryl radicals attached in positions 2 and 5

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Oppfinnelsen vedrører nye fenylderivater med formel (I), deres fremstilling og anvendelse som farmasøytisk aktive forbindelser. Forbindelsene virker spesielt som immunmodulerende midler.
NO20091553A 2006-09-21 2009-04-20 Fenylderivater og deres anvendelse som immunmodulatorer NO20091553L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2006053426 2006-09-21
PCT/IB2007/052746 WO2008035239A1 (en) 2006-09-21 2007-07-10 Phenyl derivatives and their use as immunomodulators

Publications (1)

Publication Number Publication Date
NO20091553L true NO20091553L (no) 2009-04-20

Family

ID=38753508

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091553A NO20091553L (no) 2006-09-21 2009-04-20 Fenylderivater og deres anvendelse som immunmodulatorer

Country Status (15)

Country Link
US (1) US8044076B2 (no)
EP (1) EP2069318B1 (no)
JP (1) JP5250556B2 (no)
KR (1) KR20090051774A (no)
CN (1) CN101522645B (no)
AU (1) AU2007298593A1 (no)
BR (1) BRPI0716909A2 (no)
CA (1) CA2662673A1 (no)
ES (1) ES2393412T3 (no)
IL (1) IL197693A0 (no)
MA (1) MA30784B1 (no)
MX (1) MX2009002915A (no)
NO (1) NO20091553L (no)
RU (1) RU2442780C2 (no)
WO (1) WO2008035239A1 (no)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2007002593A1 (es) 2006-09-07 2008-06-13 Actelion Pharmaceuticals Ltd Compuestos derivados de 4-heteroaril-piridina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como rechazo de organos transplantados, sindromes autoinmunes y cancer.
SI2069335T1 (sl) * 2006-09-08 2013-04-30 Actelion Pharmaceuticals Ltd. Derivati piridin-3-ila kot imunomodulacijska sredstva
CN101562977A (zh) 2006-12-15 2009-10-21 艾博特公司 新的二唑化合物
JP2010521450A (ja) * 2007-03-16 2010-06-24 アクテリオン ファーマシューティカルズ リミテッド S1p1/edg1受容体アゴニストとしてのアミノ−ピリジン誘導体
PL2195311T3 (pl) * 2007-08-17 2011-08-31 Actelion Pharmaceuticals Ltd Pochodne pirydynowe jako modulatory receptora S1P1/EDG1
CN101970430B (zh) * 2007-11-01 2013-05-08 埃科特莱茵药品有限公司 嘧啶衍生物
EP2262799B1 (en) * 2008-03-06 2012-07-04 Actelion Pharmaceuticals Ltd. Pyridine compounds
CA2714614A1 (en) * 2008-03-06 2009-09-11 Actelion Pharmaceuticals Ltd Novel pyrimidine-pyridine derivatives
SI2252609T1 (sl) * 2008-03-07 2013-07-31 Actelion Pharmaceuticals Ltd. Derivati piridin-2-ila kot imunomodulacijska sredstva
BRPI0910288A2 (pt) * 2008-03-07 2019-09-24 Actelion Pharmaceuticals Ltd composto de derivados de aminometil benzeno, composição farmacêutica que compreende esse composto e uso do mesmo.
WO2009115954A1 (en) 2008-03-17 2009-09-24 Actelion Pharmaceuticals Ltd Dosing regimen for a selective s1p1 receptor agonist
HRP20161133T1 (hr) 2008-07-23 2016-12-02 Arena Pharmaceuticals, Inc. DERIVATI SUSPSTITUIRANE 1,2,3,4-TETRAHIDROCIKLOPENTA[b]INDOL-3-IL-OCTENE KISELINE KORISNI U LIJEČENJU AUTOIMUNIH I UPALNIH POREMEĆAJA
DK2307007T3 (da) 2008-07-23 2014-11-10 Novartis Ag Sphingosin-1-phosphat-receptormodulatorer samt deres anvendelse til behandling af muskelinflammation
CN105816453B (zh) 2008-08-27 2021-03-05 艾尼纳制药公司 用于治疗自身免疫性病症和炎性病症的作为s1p1受体激动剂的经取代的三环酸衍生物
WO2010085584A1 (en) 2009-01-23 2010-07-29 Bristol-Myers Squibb Company Pyrazole-i, 2, 4 -oxad iazole derivatives as s.phing0sine-1-ph0sphate agonists
WO2010085582A1 (en) 2009-01-23 2010-07-29 Bristol-Myers Squibb Company Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases
WO2010085581A1 (en) 2009-01-23 2010-07-29 Bristol-Myers Squibb Company Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases
KR101409131B1 (ko) 2009-07-16 2014-06-17 액테리온 파마슈티칼 리미티드 피리딘-4-일 유도체
US8399451B2 (en) 2009-08-07 2013-03-19 Bristol-Myers Squibb Company Heterocyclic compounds
SI2498610T2 (sl) * 2009-11-13 2024-10-30 Receptos Llc Selektivni modulatorji receptorja sfingozin-1-fosfata in postopki kiralne sinteze
CA2786994C (en) 2010-01-27 2018-01-16 Arena Pharmaceuticals, Inc. Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
CN105503882B (zh) 2010-03-03 2019-07-05 艾尼纳制药公司 制备s1p1受体调节剂及其晶体形式的方法
ES2548683T3 (es) 2010-04-23 2015-10-20 Bristol-Myers Squibb Company Amidas del ácido 4-(5-isoxazolil o 5-pirrazolil-1,2,4-oxadiazol-3-il)-mandélico como agonistas de receptor de esfingosina-1-fosfato 1
CN103124727B (zh) 2010-07-20 2015-03-25 百时美施贵宝公司 取代的3-苯基-1,2,4-噁二唑化合物
WO2012040532A1 (en) 2010-09-24 2012-03-29 Bristol-Myers Squibb Company Substituted oxadiazole compounds and their use as s1p1 agonists
SG191742A1 (en) 2011-01-19 2013-08-30 Actelion Pharmaceuticals Ltd 2-methoxy-pyridin-4-yl derivatives
US8865754B2 (en) 2011-03-03 2014-10-21 Proteotech Inc. Compounds for the treatment of neurodegenerative diseases
US8729109B2 (en) 2011-09-08 2014-05-20 Allergan, Inc. 3-(4-(5-phenyl-1 ,2,4-oxadiazol-3-yl)phenoxy)propan-2-ol derivatives as sphingosine-1phosphate receptors modulators
SMT202000298T1 (it) 2012-08-17 2020-07-08 Actelion Pharmaceuticals Ltd Processo per la produzione di (2z,5z)-5-(3-cloro-4((r)-2,3-diidrossipropossi) benziliden)-2-(propilimmino)-3-(o-tolil)tiazolidin-4-one e intermedio usato in detto processo
CN105189487B (zh) 2013-03-15 2017-12-26 爱杜西亚药品有限公司 吡啶‑4‑基衍生物
AU2016205361C1 (en) 2015-01-06 2021-04-08 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
MY192358A (en) 2015-05-20 2022-08-17 Idorsia Pharmaceuticals Ltd Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol
US10111841B2 (en) 2015-06-19 2018-10-30 University Of South Florida Stabilization of alcohol intoxication-induced cardiovascular instability
PL3310760T3 (pl) 2015-06-22 2023-03-06 Arena Pharmaceuticals, Inc. Krystaliczna sól L-argininy kwasu (R)-2-(7-(4-cyklopentylo-3-(trifluorometylo)benzyloksy)- 1,2,3,4-tetrahydrocyklo-penta[b]indol-3-ilo)octowego do zastosowania w zaburzeniach związanych z receptorem S1P1
JP2020507610A (ja) 2017-02-16 2020-03-12 アリーナ ファーマシューティカルズ, インコーポレイテッド 腸管外症状を伴う炎症性腸疾患の治療のための化合物および方法
KR20190116416A (ko) 2017-02-16 2019-10-14 아레나 파마슈티칼스, 인크. 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법
AU2019280822A1 (en) 2018-06-06 2021-01-07 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
EP3847158A1 (en) 2018-09-06 2021-07-14 Arena Pharmaceuticals, Inc. Compounds useful in the treatment of autoimmune and inflammatory disorders
EP4173485A1 (en) 2021-10-27 2023-05-03 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Protein aggregation inhibiting compounds for plant disease control

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS51143669A (en) * 1975-06-06 1976-12-10 Takeda Chem Ind Ltd A process for preparing 1,2,4- oxadiazole derivatives
AU7686891A (en) 1990-04-05 1991-10-30 American National Red Cross, The A protein family related to immediate-early protein expressed by human endothelial cells during differentiation
JPH1046149A (ja) * 1996-07-31 1998-02-17 Canon Inc 液晶組成物の調製方法
US6423508B1 (en) 1998-03-09 2002-07-23 Smithkline Beecham Corporation Polynucleotide sequences of human EDG-1c
CN1313465C (zh) 1999-08-19 2007-05-02 Nps药物有限公司 杂多环化合物及其用于制备代谢性谷氨酸受体拮抗剂的应用
US6579880B2 (en) * 2000-06-06 2003-06-17 Ortho-Mcneil Pharmaceutical, Inc. Isoxazoles and oxadiazoles as anti-inflammatory inhibitors of IL-8
CA2438991C (en) 2001-02-21 2010-08-17 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
AU2003202994B2 (en) 2002-01-18 2007-11-22 Merck Sharp & Dohme Corp. N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as Edg receptor agonists
JP2005529923A (ja) * 2002-05-13 2005-10-06 イーライ・リリー・アンド・カンパニー 肥満および糖尿病の治療におけるメラニン凝集ホルモンアンタゴニストとして使用するための多環式化合物
JP2005533058A (ja) * 2002-06-17 2005-11-04 メルク エンド カムパニー インコーポレーテッド Edg受容体アゴニストとしての1−((5−アリール−1,2,4−オキサジアゾール−3−イル)ベンジル)アゼチジン−3−カルボキシラートおよび1−((5−アリール−1,2,4−オキサジアゾール−3−イル)ベンジル)ピロリジン−3−カルボキシラート
WO2004035538A1 (en) * 2002-10-15 2004-04-29 Merck & Co., Inc. Process for making azetidine-3-carboxylic acid
CA2524867A1 (en) 2003-05-15 2004-12-02 Merck & Co., Inc. 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists
WO2005014525A2 (en) 2003-08-12 2005-02-17 Mitsubishi Pharma Corporation Bi-aryl compound having immunosuppressive activity
CN1859908A (zh) * 2003-10-01 2006-11-08 默克公司 作为s1p受体激动剂的3,5-芳基、杂芳基或环烷基取代的-1,2,4-噁二唑类化合物
AU2004299456B2 (en) 2003-12-17 2010-10-07 Merck Sharp & Dohme Corp. (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists
JP2008500991A (ja) 2004-05-29 2008-01-17 7ティーエム ファーマ エイ/エス 医学的使用のためのcrth2レセプターリガンド
UA76239C2 (en) * 2004-06-03 2006-07-17 Labour Red Banner Order Dnipro A method for producing 2,5-di(p-aminophenyl)-1,3,4- oxadiazole
JP4318087B2 (ja) * 2004-12-13 2009-08-19 小野薬品工業株式会社 アミノカルボン酸誘導体およびその医薬用途
AU2006226018B2 (en) 2005-03-23 2012-07-12 Idorsia Pharmaceuticals Ltd Hydrogenated benzo (C) thiophene derivatives as immunomodulators
WO2006114400A1 (en) 2005-04-26 2006-11-02 Neurosearch A/S Novel oxadiazole derivatives and their medical use
JP2008545767A (ja) 2005-06-08 2008-12-18 ノバルティス アクチエンゲゼルシャフト 多環式オキサジアゾールまたはイソキサゾールおよびsip受容体リガンドとしてのそれらの使用
WO2006135694A2 (en) 2005-06-10 2006-12-21 Acadia Pharmaceuticals Inc. Uii-modulating compounds and their use
EP1896011A1 (en) 2005-06-28 2008-03-12 AstraZeneca AB New use
GB0601744D0 (en) 2006-01-27 2006-03-08 Novartis Ag Organic compounds
MX2008013990A (es) 2006-05-09 2009-01-29 Pfizer Prod Inc Derivados de cicloalquilamino acidos.
CL2007002593A1 (es) 2006-09-07 2008-06-13 Actelion Pharmaceuticals Ltd Compuestos derivados de 4-heteroaril-piridina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como rechazo de organos transplantados, sindromes autoinmunes y cancer.
SI2069335T1 (sl) 2006-09-08 2013-04-30 Actelion Pharmaceuticals Ltd. Derivati piridin-3-ila kot imunomodulacijska sredstva
US20100087491A1 (en) 2006-09-29 2010-04-08 Rainer Albert Polycyclic compounds
CN101562977A (zh) 2006-12-15 2009-10-21 艾博特公司 新的二唑化合物
WO2008091967A1 (en) 2007-01-26 2008-07-31 Smithkline Beecham Corporation Chemical compounds
JP2010521450A (ja) 2007-03-16 2010-06-24 アクテリオン ファーマシューティカルズ リミテッド S1p1/edg1受容体アゴニストとしてのアミノ−ピリジン誘導体
CN101970430B (zh) 2007-11-01 2013-05-08 埃科特莱茵药品有限公司 嘧啶衍生物
CA2714614A1 (en) 2008-03-06 2009-09-11 Actelion Pharmaceuticals Ltd Novel pyrimidine-pyridine derivatives
EP2262799B1 (en) 2008-03-06 2012-07-04 Actelion Pharmaceuticals Ltd. Pyridine compounds
SI2252609T1 (sl) 2008-03-07 2013-07-31 Actelion Pharmaceuticals Ltd. Derivati piridin-2-ila kot imunomodulacijska sredstva
BRPI0910288A2 (pt) 2008-03-07 2019-09-24 Actelion Pharmaceuticals Ltd composto de derivados de aminometil benzeno, composição farmacêutica que compreende esse composto e uso do mesmo.

Also Published As

Publication number Publication date
EP2069318A1 (en) 2009-06-17
RU2442780C2 (ru) 2012-02-20
IL197693A0 (en) 2009-12-24
BRPI0716909A2 (pt) 2013-11-05
US20100087495A1 (en) 2010-04-08
ES2393412T3 (es) 2012-12-21
MX2009002915A (es) 2009-03-31
CN101522645A (zh) 2009-09-02
MA30784B1 (fr) 2009-10-01
CN101522645B (zh) 2013-01-09
JP5250556B2 (ja) 2013-07-31
WO2008035239A1 (en) 2008-03-27
CA2662673A1 (en) 2008-03-27
US8044076B2 (en) 2011-10-25
EP2069318B1 (en) 2012-09-12
AU2007298593A1 (en) 2008-03-27
RU2009114749A (ru) 2010-10-27
JP2010504320A (ja) 2010-02-12
KR20090051774A (ko) 2009-05-22

Similar Documents

Publication Publication Date Title
NO20076648L (no) Novel thiophene derivatives
NO20090628L (no) Pyridizinon derivativater
NO20083427L (no) Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse
NO20091395L (no) Nye tiofenderivater
NO20091409L (no) Pyridin-3-yl-derivater som immunmodulerende midler
NO20071593L (no) Pyrimidinderivater
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
NO20074275L (no) 2- (4-okso-4H-kinazolin-3-yl) acetamider og deres anvendelse som Vasopressin-V3-antagonister
NO20072963L (no) 5-substituerte kinolin- og isokinolinderivater, fremgangsmate for deres fremstilling og deres anvendelse som betennelseshemmere
NO20082090L (no) Pyridopyrimidinoninhibitorer av P13K alfa
NO20082793L (no) Nye tiofenderivater
NO20073791L (no) Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer
NO20091889L (no) Inhibitorer av spiroketon acetyl-CoA karboksylase
EA201200049A1 (ru) 1,3-дизамещенные производные имидазолидин-2-она в качестве ингибиторов cyp 17
EA201100503A1 (ru) Глюкозидные производные и их применения
NO20080675L (no) P38-Map kinaseinhibitorer og metoder for deres anvendelse
NO20075299L (no) Hydrogenated benzo (c) thiophene derivatives as immunomodulators
NO20084418L (no) Azolopyridin-3-on derivater som inhibitorer av endoteliallipase
NO20071504L (no) Pyrimidinderivanter.
NO20066055L (no) Pyridinderivater
NO20081942L (no) Karbamoylbenzotriazolderivater som inhibitorer av lipaser og fosfolipaser
NO20082496L (no) Pyrazinderivater
NO20090994L (no) 2-aminobenzoxazol karboxamider som 5HT3 modulatorer
NO20081217L (no) Nye benzotiazolonderivater
NO20081001L (no) Derivater av karboksamid som antagonister for muskarinisk reseptor

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application